These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12235005)

  • 1. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
    Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F
    Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.
    Doñate F; Juarez JC; Guan X; Shipulina NV; Plunkett ML; Tel-Tsur Z; Shaw DE; Morgan WT; Mazar AP
    Cancer Res; 2004 Aug; 64(16):5812-7. PubMed ID: 15313924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells.
    Guan X; Juarez JC; Qi X; Shipulina NV; Shaw DE; Morgan WT; McCrae KR; Mazar AP; Doñate F
    Thromb Haemost; 2004 Aug; 92(2):403-12. PubMed ID: 15269838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Domain structure and conformation of histidine-proline-rich glycoprotein.
    Borza DB; Tatum FM; Morgan WT
    Biochemistry; 1996 Feb; 35(6):1925-34. PubMed ID: 8639676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
    He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
    Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein.
    Thulin A; Ringvall M; Dimberg A; Kårehed K; Väisänen T; Väisänen MR; Hamad O; Wang J; Bjerkvig R; Nilsson B; Pihlajaniemi T; Akerud H; Pietras K; Jahnen-Dechent W; Siegbahn A; Olsson AK
    Mol Cancer Res; 2009 Nov; 7(11):1792-802. PubMed ID: 19903770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
    Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein.
    Dixelius J; Olsson AK; Thulin A; Lee C; Johansson I; Claesson-Welsh L
    Cancer Res; 2006 Feb; 66(4):2089-97. PubMed ID: 16489009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of human thrombomodulin domain as a novel angiogenic factor.
    Shi CS; Shi GY; Chang YS; Han HS; Kuo CH; Liu C; Huang HC; Chang YJ; Chen PS; Wu HL
    Circulation; 2005 Apr; 111(13):1627-36. PubMed ID: 15795324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
    Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
    Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S
    Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
    He GA; Luo JX; Zhang TY; Wang FY; Li RF
    Biochem Biophys Res Commun; 2003 Dec; 312(3):801-5. PubMed ID: 14680836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.
    Watanabe J; Endo Y; Shimada N; Natsume T; Sasaki T; Kobayashi M
    In Vivo; 2007; 21(2):297-304. PubMed ID: 17436580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
    Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.